Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100 Caserta, Italy.
Molecular Immunology and Immunoregulation, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS-Napoli, 80131 Naples, Italy.
Bioorg Med Chem. 2018 May 15;26(9):2539-2550. doi: 10.1016/j.bmc.2018.04.017. Epub 2018 Apr 7.
Cationic nucleopeptides belong to a family of synthetic oligomers composed by amino acids and nucleobases. Their capability to recognize nucleic acid targets and to cross cellular membranes provided the basis for considering them as novel non-covalent delivery agents for nucleic acid pharmaceuticals. Herein, starting from a 12-mer nucleopeptide model, the number of cationic residues was modulated in order to obtain new nucleopeptides endowed with high solubility in acqueous medium, acceptable bio-stability, low cytotoxicity and good capability to bind nucleic acid. Two candidates were selected to further investigate their potential as nucleic acid carriers, showing higher efficiency to deliver PNA in comparison with RNA. Noteworthy, this study encourages the development of nucleopeptides as new carriers to extend the known strategies for those nucleic acid analogues, especially PNA, that still remain difficult to drive into the cells.
阳离子核肽属于一类由氨基酸和碱基组成的合成寡聚物。它们能够识别核酸靶标并穿过细胞膜,这为将其用作核酸药物的新型非共价递药载体提供了依据。在本文中,我们从一个 12 聚体核肽模型开始,调节阳离子残基的数量,以获得新的核肽,使其在水相介质中具有高溶解性、可接受的生物稳定性、低细胞毒性和与核酸结合的良好能力。选择了两种候选物来进一步研究它们作为核酸载体的潜力,结果表明它们比 RNA 具有更高的 PNA 递药效率。值得注意的是,这项研究鼓励开发核肽作为新的载体,以扩展那些核酸类似物(尤其是 PNA)的已知策略,因为这些核酸类似物仍然难以进入细胞。